From the reviews: "For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg ... offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters ... focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed." (SciTech Book News, December, 2010) "The 36 chapters in this book ... read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. ... suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. ... An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. ... an excellent resource for readers interested in the management of advanced prostate cancer ... ." (Jianqing Lin, Doody's Review Service, December, 2010) "This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. ... this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now." (M. Hornak, Neoplasma, March, 2011) "This textbook by W.D. Figg and co-authors ... makes an exhaustive overview of present and future medical therapies of prostate cancer. ... This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All chapters are concise and most of them are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management." (European Urology Today, April/May, 2011)

• Cell Biology of Prostate Cancer and Molecular Targets.- Cell Biology of Prostate Cancer and Molecular Targets.- Hormone Therapy.- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer.- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer.- Androgens and Prostate Cancer.- Androgen Receptor Biology in Prostate Cancer.- Androgen Receptor Antagonists.- 5-Alpha Reductase Inhibitors in Prostate Cancer.- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer.- Androgen Deprivation Therapy.- Pharmacogenetics of the Androgen Metabolic Pathway.- Chemotherapy.- Mitoxantrone.- Docetaxel.- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer.- Platinum Agents in Prostate Cancer.- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer.- Microtubule Targeting Agents.- Angiogenesis.- Principles of Antiangiogenic Therapy.- Bevacizumab in Advanced Prostate Cancer.- Thalidomide and Analogs.- Investigational Angiogenesis Inhibitors.- Pharmacogenetics of Angiogenesis.- Bone Metastasis.- Pathophysiology of Prostate Cancer Bone Metastasis.- Radiopharmaceuticals.- Bisphosphonates for Prevention and Treatment of Bone Metastases.- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer.- Calcitriol and Vitamin D Analogs.- Immunotherapy.- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches.- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer.- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX.- CTLA-4 Blockade for Prostate Cancer Treatment.- Prevention.- Prostate Cancer Chemoprevention Strategies.- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk.- Inflammation as a Target in Prostate Cancer.- Drug Development.- Challenges for the Development of New Agents in Prostate Cancer.- FDA Approval ofProstate Cancer Treatments.- Applications of Proteomics in Prostate Cancer.- Erratum to: Docetaxel.- Erratum to: Docetaxel.

From the reviews: "For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg ... offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters ... focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed." (SciTech Book News, December, 2010) "The 36 chapters in this book ... read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. ... suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. ... An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. ... an excellent resource for readers interested in the management of advanced prostate cancer ... ." (Jianqing Lin, Doody's Review Service, December, 2010) "This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. ... this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now." (M. Hornak, Neoplasma, March, 2011) "This textbook by W.D. Figg and co-authors ... makes an exhaustive overview of present and future medical therapies of prostate cancer. ... This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All chapters are concise and most of them are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management." (European Urology Today, April/May, 2011)

• Cell Biology of Prostate Cancer and Molecular Targets.- Cell Biology of Prostate Cancer and Molecular Targets.- Hormone Therapy.- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer.- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer.- Androgens and Prostate Cancer.- Androgen Receptor Biology in Prostate Cancer.- Androgen Receptor Antagonists.- 5-Alpha Reductase Inhibitors in Prostate Cancer.- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer.- Androgen Deprivation Therapy.- Pharmacogenetics of the Androgen Metabolic Pathway.- Chemotherapy.- Mitoxantrone.- Docetaxel.- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer.- Platinum Agents in Prostate Cancer.- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer.- Microtubule Targeting Agents.- Angiogenesis.- Principles of Antiangiogenic Therapy.- Bevacizumab in Advanced Prostate Cancer.- Thalidomide and Analogs.- Investigational Angiogenesis Inhibitors.- Pharmacogenetics of Angiogenesis.- Bone Metastasis.- Pathophysiology of Prostate Cancer Bone Metastasis.- Radiopharmaceuticals.- Bisphosphonates for Prevention and Treatment of Bone Metastases.- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer.- Calcitriol and Vitamin D Analogs.- Immunotherapy.- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches.- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer.- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX.- CTLA-4 Blockade for Prostate Cancer Treatment.- Prevention.- Prostate Cancer Chemoprevention Strategies.- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk.- Inflammation as a Target in Prostate Cancer.- Drug Development.- Challenges for the Development of New Agents in Prostate Cancer.- FDA Approval ofProstate Cancer Treatments.- Applications of Proteomics in Prostate Cancer.- Erratum to: Docetaxel.- Erratum to: Docetaxel.

From the reviews: "For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg ... offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters ... focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed." (SciTech Book News, December, 2010) "The 36 chapters in this book ... read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. ... suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. ... An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. ... an excellent resource for readers interested in the management of advanced prostate cancer ... ." (Jianqing Lin, Doody's Review Service, December, 2010) "This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. ... this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now." (M. Hornak, Neoplasma, March, 2011) "This textbook by W.D. Figg and co-authors ... makes an exhaustive overview of present and future medical therapies of prostate cancer. ... This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All chapters are concise and most of them are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management." (European Urology Today, April/May, 2011)

• Cell Biology of Prostate Cancer and Molecular Targets.- Cell Biology of Prostate Cancer and Molecular Targets.- Hormone Therapy.- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer.- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer.- Androgens and Prostate Cancer.- Androgen Receptor Biology in Prostate Cancer.- Androgen Receptor Antagonists.- 5-Alpha Reductase Inhibitors in Prostate Cancer.- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer.- Androgen Deprivation Therapy.- Pharmacogenetics of the Androgen Metabolic Pathway.- Chemotherapy.- Mitoxantrone.- Docetaxel.- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer.- Platinum Agents in Prostate Cancer.- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer.- Microtubule Targeting Agents.- Angiogenesis.- Principles of Antiangiogenic Therapy.- Bevacizumab in Advanced Prostate Cancer.- Thalidomide and Analogs.- Investigational Angiogenesis Inhibitors.- Pharmacogenetics of Angiogenesis.- Bone Metastasis.- Pathophysiology of Prostate Cancer Bone Metastasis.- Radiopharmaceuticals.- Bisphosphonates for Prevention and Treatment of Bone Metastases.- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer.- Calcitriol and Vitamin D Analogs.- Immunotherapy.- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches.- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer.- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX.- CTLA-4 Blockade for Prostate Cancer Treatment.- Prevention.- Prostate Cancer Chemoprevention Strategies.- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk.- Inflammation as a Target in Prostate Cancer.- Drug Development.- Challenges for the Development of New Agents in Prostate Cancer.- FDA Approval ofProstate Cancer Treatments.- Applications of Proteomics in Prostate Cancer.- Erratum to: Docetaxel.- Erratum to: Docetaxel.